Vijaya Diagnostic Centre Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Strong quarter, margin-led beat: Revenue grew 26.6% YoY on broad-based volume and wellness momentum, while EBITDA margin hit 43.5% as new hubs broke even faster than planned.
• New centers are breakeven machines: Two hubs launched in Q3 broke even within two quarters, beating the three-quarter guided timeline, and full-year OPEX burn from new centers was just ~0.8% against an envisioned 2-2.5%.
• Hyderabad is the margin engine: The mature core market grew ~20%, providing the operating leverage that lets the company fund expansion while guiding to 40%+ EBITDA margins.
• Bangalore is the next big bet: A flagship center with high-end imaging opens in months, two more locations are finalized, and management expects to deploy capital there for 5-7 years.
• What to watch next quarter: Whether the 1-1.5% price hike lands in Q1 or Q2, the pace of Bangalore hub ramp-ups, and any inorganic move given 8-15 assets cross management's desk each year.

Quarter in Review: Volume, Mix and Margin

• Revenue growth was volume-led: 26.6% YoY growth came from both pathology and radiology, aided by favorable seasonality, wellness momentum, network expansion, and brand traction in new markets. No specific flu or illness drove the quarter.
• Revenue per test rose on mix shift: A 4.3% increase reflected new hubs in Bangalore and West Bengal where first-year revenue is still radiology-heavy, shifting the overall test mix rather than signaling broad-based price increases.
• Hyderabad delivered ~20% growth: The mature market gained share as the largest player with a 40+ year presence, wide service range, high-end technology, and pricing at market rates with only 2-3% variance.
• PH Diagnostics grew 16% YoY: Driven by network expansion and favorable seasonality; the Ambegaon center achieved breakeven in one year, in line with guidance.
• Pune grew 16% YoY: Growth came from a mix of new center additions and low-single-digit growth in existing centers, with some capacity constraint. Management acknowledged Pune was the only geography where the three-year-ago doubling plan did not materialize, attributing the delay to a 1-1.5 year post-acquisition alignment period.
• Kolkata ramp-up is on track: The VIP Road hub saw double-digit YoY growth; Medinova runs at full capacity; two hubs added in Q1 FY26 achieved breakeven in under nine months.

Reddy: "sustainable financial performance is ultimately a by-product of a discipline and a purpose-driven approach."

Margin Delivery: Operating Leverage in a Fixed-Cost Business

• EBITDA margin hit 43.5%, up 379 bps YoY: The expansion was driven by operating leverage in the existing network, faster-than-expected breakeven of new hubs, and Hyderabad growing at 20%.
• New-center OPEX burn was a fraction of plan: Full-year burn was ~0.8% versus the envisioned 2-2.5%, meaning new centers are contributing positively far earlier than modeled.
• Management guided conservatively and promised more: The official margin guidance is 40%, but the CFO explicitly committed to delivering a better number while continuing to open new centers.
• Cost-lever detail was not quantified: When asked for specific cost-line contributions beyond operating leverage, management stayed at the general level, pointing to faster breakeven and fixed-cost absorption without breaking out individual line items.

Raju: "while the guidance would be 40%, we'll try to deliver a better number than that."

Network Expansion: Bangalore Takes Center Stage

• FY27 expansion plan is 4-5 hubs and 10-12 spokes: Capex guidance of INR 140-150 crores covers executed leases only and will be revised quarterly as more projects are signed. Of this, INR 120-130 crores goes to new centers and ~INR 10-12 crores to replacement capex.
• Bangalore flagship is imminent: The Bannerghatta center, announced in Q3 FY26, will house high-end PET CT, high-end MRI, cardiac CT, digital cardiac PET CT, and a wide-bore Omega MRI (only a few in India). It is expected ready in the next couple of months.
• Two more Bangalore locations finalized: One in Bannerghatta/JP Nagar and one in Rajajinagar, with more hubs being scouted. Management expects to deploy capital in Bangalore for the next 5-7 years.
• Core-market hubs are breaking even faster than guided: Khammam and Nandyal hubs, launched in Q3 FY26, achieved breakeven within two quarters against a three-quarter guided timeline for core-market hubs.
• Pune hubs expected to take a full year: New hubs like Ambegaon and Kalyani Nagar are expected to take the full one year for breakeven, consistent with the guided timeline for non-core markets.
• No North India for 3-5 years: Management called it a strategic decision, saying their hands are full building denser networks in Karnataka, West Bengal, and Pune.

Reddy: "Hands are full, trying to build denser networks in two new states that we've acquired. So it's a very strategic decision that we do not want to grow in North."

Competitive Positioning and Channel Dynamics

• Hospitals are not direct competitors for OPD diagnostics: Hospital labs cater mainly to in-patients; their OPD diagnostics are 20-25% costlier than Vijaya's, positioning Vijaya as the affordable, focused alternative.
• Online aggregators have had limited impact: Many are asset-light players without their own labs who outsource diagnostics to Vijaya or other players, making them a channel rather than a threat.
• Corporate wellness sees churn from price sensitivity: Some large corporates have been retained for 2-3 years, but aggregators and price sensitivity drive churn in this segment.
• Wellness repeat-customer data is still immature: The company started tracking only two years back with new systems and needs 2-3 more years of data to comment on repeat versus first-time user patterns.
• GLP-1 drug impact is negligible so far: Management has hardly seen requests for a proper GLP package and finds it difficult to track since prescriptions do not always name the drug.

Reddy: "Hospitals are basically probably designed to take care of the needs of their in-patients. So, if you look at their labs, which are more or less like back in kitchens, they have to cater to their in-patients."

Technology and Digital Investments

• AI radiology patches are rolling out gradually: A few AI solutions were onboarded in Q4 (CT KUB, dental scans), with talks underway for lung, liver, and brain modalities. Only 6-7 AI patches are likely to be available for release to customers; 2-3 are already done, and more will layer on as approvals come.
• CRM and ERP implementation is underway: Work started in the last financial year and will launch in the current financial year.
• Digital marketing spend to double: Costs are expected to double in the current and next financial year as the company invests in brand traction in new markets.
• Technology investments will continue for 1-2 years: Ongoing spend on systems, AI, and digital infrastructure is baked into the outlook.
• A state-of-the-art automated lab is coming: The Panjagutta, Hyderabad facility will feature a fully automated track system to enhance turnaround times and operational productivity.
• Genomic testing is a long-term play: One central lab in Hyderabad will cater to all six geographies, but no significant revenue is expected in the next few years.

Inorganic Strategy and Capital Allocation

• 8-15 assets come to management yearly: The company is selective, evaluating only B2C-driven assets with matching ethos and reasonable valuation.
• A new cluster would come only via acquisition: Management would need the target to be large enough to justify taking on another cluster, and no such opportunity is currently shortlisted.
• No inorganic move planned for Pune: Management prefers to expand the PH brand organically rather than acquire another asset in the same geography.
• Franchise model is off the table: All centers will remain company-owned and company-operated.

Reddy: "if something comes up, there's almost close to about 8 to 15 assets that come to us on a yearly basis. But we are very, very conscious about what we bring on to the table to the Board and to our shareholders because it needs to add value."

Guidance & Commitments

Key Metrics